COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
申请人:Plexxikon Inc.
公开号:US20170158690A1
公开(公告)日:2017-06-08
Disclosed are compounds of Formula I:
or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein Z
2
, Z
3
, and Z
5
are as described herein, compositions thereof, and uses thereof.
[EN] BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY<br/>[FR] COMPOSÉS BIARYLIQUES UTILES POUR LE TRAITEMENT DE MALADIES HUMAINES EN ONCOLOGIE, NEUROLOGIE ET IMMUNOLOGIE
申请人:BIOGEN IDEC INC
公开号:WO2015089327A1
公开(公告)日:2015-06-18
The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
Poly(fluoroalkyl acrylate)-Bound Ruthenium Carbene Complex: A Fluorous and Recyclable Catalyst for Ring-Closing Olefin Metathesis
作者:Qingwei Yao、Yiliang Zhang
DOI:10.1021/ja037394p
日期:2004.1.1
The synthesis of a fluorous olefin metathesiscatalyst derived from the Grubbs second-generation ruthenium carbene complex is described. The air stable fluorous polymer-bound ruthenium carbene complex 1 shows high reactivity in effecting the ring-closingmetathesis of a broad spectrum of diene and enyne substrates leading to the formation of di-, tri-, and tetrasubstituted cyclic olefins in minimally
Immobilization of the Grubbs second-generation ruthenium-carbene complex on poly(ethylene glycol): a highly reactive and recyclable catalyst for ring-closing and cross-metathesis
作者:Qingwei Yao、Adalie Rodriguez Motta
DOI:10.1016/j.tetlet.2004.01.036
日期:2004.3
catalyst derived from the Grubbs second-generation Ru carbene complex was synthesized and shown to be highly reactive in the ring-closing metathesis of a wide variety of diene substrates, yielding di-, tri-, and tetra-substituted carbocyclic and heterocyclic olefins. The immobilized catalyst also proved to be highly reactive and recyclable in cross-metathesis and ring-opening/cross-metathesis. In all cases
[EN] INHIBITORS OF INTERLEUKIN-1 RECEPTOR ASSOCIATED KINASE (IRAK) /FMS-LIKE RECEPTOR TYROSINE KINASE (FLT3), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF<br/>[FR] INHIBITEURS DE LA KINASE ASSOCIÉE AU RÉCEPTEUR DE L'INTERLEUKINE 1 (IRAK)/TYROSINE KINASE DU RÉCEPTEUR DE TYPE FMS (FLT3), LEURS PRODUITS PHARMACEUTIQUES ET LEURS PROCÉDÉS
申请人:PHARMABLOCK SCIENCES NANJING INC
公开号:WO2021159993A1
公开(公告)日:2021-08-19
Inhibitors of interleukin-1 receptor associated kinase (IRAK) enzyme/FMS-like receptor tyrosine kinase (FLT3) with Formula (I), a pharmaceutically acceptable salt, ester, prodrug, complex, solvate, hydrate, or isomer thereof, in any crystalline form or in amorphous form. In Formula (I), X, X 1, X 2 is selected from N and C; and U, V and W groups are independently of each other a non-hydrogen monovalent group. Pharmaceutical products comprising the IRAK inhibitors and prophylaxis and/or treatment of inflammatory diseases, autoimmune diseases, and proliferative diseases, among others, are also provided. The interleukin-1 receptor associated kinase (IRAK) mentioned above can be IRAK4.